{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:18:49Z","timestamp":1792030729236,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1378\/chest.125.2.580","type":"journal-article","created":{"date-parts":[[2004,2,9]],"date-time":"2004-02-09T23:18:22Z","timestamp":1076368702000},"page":"580-586","source":"Crossref","is-referenced-by-count":102,"title":["Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension"],"prefix":"10.1016","volume":"125","author":[{"given":"Hanno H.","family":"Leuchte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schwaiblmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer A.","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus F.","family":"Neurohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Kolbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.125.2.580_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension: results from a national prospective study","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.125.2.580_bib2","doi-asserted-by":"crossref","first-page":"51A","DOI":"10.1016\/S0002-9149(99)80383-X","article-title":"Pathology and pathophysiology of primary pulmonary hypertension","volume":"75","author":"Rubin","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.125.2.580_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1161\/01.CIR.42.6.1163","article-title":"Primary pulmonary hypertension: a pathological study of the lung vessels in 156 clinically diagnosed cases","volume":"42","author":"Wagenvoort","year":"1970","journal-title":"Circulation"},{"key":"10.1378\/chest.125.2.580_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.70.4.580","article-title":"Primary pulmonary hypertension: natural history and the importance of thrombosis","volume":"70","author":"Fuster","year":"1984","journal-title":"Circulation"},{"key":"10.1378\/chest.125.2.580_bib5","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1378\/chest.112.3.714","article-title":"The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension","volume":"112","author":"Frank","year":"1997","journal-title":"Chest"},{"key":"10.1378\/chest.125.2.580_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(98)02111-4","article-title":"Primary pulmonary hypertension","volume":"352","author":"Gaine","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.125.2.580_bib7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1164\/ajrccm\/140.6.1623","article-title":"The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registration Primary Pulmonary Hypertension","volume":"140","author":"Weir","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.125.2.580_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.125.2.580_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1183\/09031936.98.12020265","article-title":"Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium channel blockers in primary pulmonary hypertension","volume":"12","author":"Sitbon","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.125.2.580_bib10","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0735-1097(98)00361-1","article-title":"Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine","volume":"32","author":"Ricciardi","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.125.2.580_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.125.2.580_bib12","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.125.2.580_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-132-6-200003210-00003","article-title":"Inhaled iloprost to treat severe pulmonary hypertension (an uncontrolled trial)","volume":"132","author":"Olschewski","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.125.2.580_bib14","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1161\/01.CIR.101.20.2388","article-title":"Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension;","volume":"101","author":"Wensel","year":"2000","journal-title":"Circulation"},{"key":"10.1378\/chest.125.2.580_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0735-1097(99)00494-5","article-title":"A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension","volume":"35","author":"Hoeper","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.125.2.580_bib16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","article-title":"Aerosolized prostacyclin and iloprost in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.125.2.580_bib17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","article-title":"Long-term treatment with continuous intravenous epoprostenol (prostacyclin) in primary pulmonary hypertension","volume":"1","author":"Higgenbottam","year":"1984","journal-title":"Lancet"},{"key":"10.1378\/chest.125.2.580_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension;","volume":"338","author":"Mc Laughlin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.125.2.580_bib19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuos intravenous epoprostenol with conventional therapy for primary pulmonary hypertension;","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.125.2.580_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuos intravenous prostacyclin (epoprostenol): results of randomised trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.125.2.580_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1164\/ajrccm.163.2.2003021","article-title":"Sildenafil modulates hemodynamic and pulmonary gas exchange","volume":"163","author":"Kleinsasser","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.125.2.580_bib22","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1136\/heart.84.2.e4","article-title":"Sildenafil: a selective pulmonary vasodilator in childhood primary pulmonary hypertension","volume":"84","author":"Abrams","year":"2000","journal-title":"Heart"},{"key":"10.1378\/chest.125.2.580_bib23","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM200011023431814","article-title":"Sildenafil in primary pulmonary hypertension [letter]","volume":"343","author":"Prasad","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.125.2.580_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000542-199907000-00041","article-title":"Sildenafil ameliorates effects of nitric oxide withdrawal","volume":"91","author":"Atz","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1378\/chest.125.2.580_bib25","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/00000542-200006000-00044","article-title":"Sildenafil can increase the response to nitric oxide","volume":"92","author":"Bigatello","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1378\/chest.125.2.580_bib26","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.125.2.580_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.125.2.580_bib28","author":"Rich"},{"key":"10.1378\/chest.125.2.580_bib29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.CIR.93.3.484","article-title":"Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension","volume":"93","author":"Raffy","year":"1996","journal-title":"Circulation"},{"key":"10.1378\/chest.125.2.580_bib30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(91)92033-X","article-title":"Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension","volume":"338","author":"Pepke-Zaba","year":"1991","journal-title":"Lancet"},{"key":"10.1378\/chest.125.2.580_bib31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1164\/ajrccm.151.2.7842196","article-title":"Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin","volume":"151","author":"Sitbon","year":"1995","journal-title":"Am J Respir Crit Care"},{"key":"10.1378\/chest.125.2.580_bib32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for the treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.125.2.580_bib33","first-page":"L536","article-title":"Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors","volume":"266","author":"Rabe","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1378\/chest.125.2.580_bib34","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","article-title":"Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms","volume":"75","author":"Beavo","year":"1995","journal-title":"Physiol Rev"},{"key":"10.1378\/chest.125.2.580_bib35","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","article-title":"Oral sildenafil in treatment of erectile dysfunction","volume":"338","author":"Goldstein","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.125.2.580_bib36","doi-asserted-by":"crossref","first-page":"13C","DOI":"10.1016\/S0002-9149(99)00043-0","article-title":"Effects of sildenafil citrate on human hemodynamics","volume":"83","author":"Jackson","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.125.2.580_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.RES.65.1.1","article-title":"Biological actions and properties of the endothelium derived nitric oxide formed and released for artery and vein","volume":"65","author":"Ignarro","year":"1989","journal-title":"Circ Res"},{"key":"10.1378\/chest.125.2.580_bib38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.pa.30.040190.002535","article-title":"Biosynthesis and metabolism of endothelium-derived nitric oxide","volume":"30","author":"Ignarro","year":"1990","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1378\/chest.125.2.580_bib39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-2952(91)90618-F","article-title":"Signal transduction mechanisms involving nitric oxide","volume":"41","author":"Ignarro","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"10.1378\/chest.125.2.580_bib40","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1152\/jappl.1995.78.4.1288","article-title":"Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs","volume":"78","author":"Ichinose","year":"1995","journal-title":"J Appl Physiol"},{"key":"10.1378\/chest.125.2.580_bib41","doi-asserted-by":"crossref","first-page":"L1361","DOI":"10.1152\/ajplung.2001.281.6.L1361","article-title":"Combination of non specific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension","volume":"281","author":"Schermuly","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215318675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215318675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T13:36:34Z","timestamp":1531143394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215318675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0012369215318675"],"URL":"https:\/\/doi.org\/10.1378\/chest.125.2.580","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}